Alteogen Inc (196170)

Currency in KRW
479,000
+3,000(+0.63%)
Closed·
196170 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
196170 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
472,500484,000
52 wk Range
242,000508,000
Key Statistics
Bid/Ask
479,000.00 / 479,500.00
Prev. Close
476,000
Open
483,500
Day's Range
472,500-484,000
52 wk Range
242,000-508,000
Volume
218.44K
Average Volume (3m)
397.06K
1-Year Change
80.49%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
196170 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
565,000
Upside
+17.95%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Alteogen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Alteogen Inc Company Profile

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; and Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.

Employees
155

Compare 196170 to Peers and Sector

Metrics to compare
196170
Peers
Sector
Relationship
P/E Ratio
204.4x−10.4x−0.5x
PEG Ratio
0.54−0.100.00
Price/Book
69.1x2.3x2.6x
Price / LTM Sales
167.7x9.3x3.2x
Upside (Analyst Target)
18.7%6.8%42.7%
Fair Value Upside
Unlock5.0%5.8%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 565,000
(+17.95% Upside)

Earnings

Latest Release
May 19, 2025
EPS / Forecast
1,550.00 / --
Revenue / Forecast
83.70B / 17.70B
EPS Revisions
Last 90 days

196170 Income Statement

People Also Watch

63,400
034020
+1.28%
55,000
035720
-2.65%
269,000
000660
+0.19%
144,200
141080
+0.14%
125,200
000100
+0.16%

FAQ

What Stock Exchange Does Alteogen Trade On?

Alteogen is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for Alteogen?

The stock symbol for Alteogen is "196170."

What Is the Alteogen Market Cap?

As of today, Alteogen market cap is 25.44T.

What Is Alteogen's Earnings Per Share (TTM)?

The Alteogen EPS (TTM) is 2,339.87.

When Is the Next Alteogen Earnings Date?

Alteogen will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is 196170 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alteogen Stock Split?

Alteogen has split 4 times.

How Many Employees Does Alteogen Have?

Alteogen has 155 employees.

What is the current trading status of Alteogen (196170)?

As of 23 Jul 2025, Alteogen (196170) is trading at a price of 479,000.00, with a previous close of 476,000.00. The stock has fluctuated within a day range of 472,500.00 to 484,000.00, while its 52-week range spans from 242,000.00 to 508,000.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.